12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Wednesday's pre-market session, several healthcare stocks showed significant movement. Chemomab Therapeutics, Heart Test Laboratories, Kinnate Biopharma, Heron Therapeutics, Solid Biosciences, and Cormedix experienced gains, with Chemomab leading at a 65.6% increase. On the losing side, Graphite Bio, SILO Pharma, GT Biopharma, Tivic Health Systems, Aditxt, and Varex Imaging saw their stock prices fall, with Graphite Bio dropping by 14.6%. The movements were largely attributed to recent Q3 and Q4 earnings reports.
November 15, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aditxt's shares fell 9.94% to $4.35, with a market value of $1.9 million.
Aditxt's stock price decline may continue to affect investor confidence negatively in the short term.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Graphite Bio's stock fell 14.6% to $1.99, with a market cap of $115.3 million.
The decline in Graphite Bio's stock price could indicate negative investor sentiment, potentially leading to further short-term downside.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
GT Biopharma's stock decreased by 11.12% to $0.2, with a market cap of $8.2 million.
GT Biopharma's stock decline could suggest negative market sentiment, potentially affecting the stock negatively in the short term.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
SILO Pharma's shares decreased by 11.54% to $1.15, with a market cap of $3.5 million.
SILO Pharma's stock decrease may reflect investor concerns, possibly leading to further short-term declines.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Tivic Health Systems' stock declined by 10.1% to $1.96 after their Q3 earnings report, with a market value of $2.8 million.
The drop in Tivic Health Systems' stock price post-Q3 earnings could indicate investor disappointment, likely leading to a negative short-term impact.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Varex Imaging's stock decreased by 9.64% to $17.54 after their Q4 earnings report, with a market value of $708.6 million.
Varex Imaging's stock price drop following their Q4 earnings suggests a negative investor response, which could lead to further short-term declines.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Chemomab Therapeutics' stock soared by 65.6% to $1.01, with a market value of $11.3 million after their Q3 earnings report.
The significant pre-market gain for Chemomab Therapeutics is likely due to a positive reception of their Q3 earnings report, which could lead to continued investor interest in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Cormedix shares increased by 21.72% to $3.81, with a market cap of $208.8 million after their Q3 earnings.
Cormedix's stock appreciation is likely due to their Q3 earnings report, which could lead to short-term bullish behavior.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Heron Therapeutics' stock climbed by 25.92% to $0.68, with a market value of $95.7 million after their Q3 earnings report.
Heron Therapeutics' stock price increase is likely influenced by their Q3 earnings report, suggesting a positive short-term outlook.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Heart Test Laboratories' stock increased by 41.85% to $0.26, with a market cap of $2.7 million.
Heart Test Laboratories' significant stock increase may attract short-term investor attention, although the low market cap suggests potential volatility.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Kinnate Biopharma's shares rose by 35.66% to $2.13, with a market value of $100.3 million following their Q3 earnings.
The positive movement in Kinnate Biopharma's stock price is likely a reaction to their recent Q3 earnings, indicating potential short-term growth.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Solid Biosciences' stock rose 25.35% to $2.67, with a market cap of $53.8 million.
The rise in Solid Biosciences' stock price may draw short-term interest, but the lack of specific news suggests the need for caution.
CONFIDENCE 65
IMPORTANCE 60
RELEVANCE 70